Craig-Hallum Assumes DiaMedica Therapeutics at Buy, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alexander Nowak assumes coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and sets a price target of $8.
April 24, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DiaMedica Therapeutics receives a Buy rating from Craig-Hallum with a price target of $8.
The initiation of coverage by a reputable analyst with a Buy rating and a specific price target can significantly influence investor perception and stock price. Given the positive outlook and the setting of a price target at $8, this is likely to generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100